natgillin/translations-raw huggingface dataset:
Leflunomide Teva 10 mg tablets leflunomide
Leflunomid Teva 10 mg filmsko obložene tablete leflunomid
Leflunomide Teva 20 mg film-coated tablets
Leflunomid Teva 20 mg filmsko obložene tablete
Leflunomide Teva 20 mg film-coated tablets are dark beige, triangle shaped, film-coated tablets, engraved with ”20” on one side and “L” on the other.
Leflunomid Teva 20 mg filmsko obložene tablete so temno rjavkaste, trikotne filmsko obložene tablete, z vgravirano oznako »20« na eni strani in »L« na drugi strani tablete.
Leflunomide Teva 20 mg tablets leflunomide
Leflunomid Teva 20 mg filmsko obložene tablete leflunomid
Leflunomide Teva belongs to a group of medicines called anti-rheumatic medicines.
Zdravilo Leflunomid Teva spada v skupino zdravil, ki jih imenujemo antirevmatična zdravila.
Leflunomide Teva can occasionally cause some problems with your blood, liver, lungs, or nerves in your arms or legs.
Občasno lahko zdravilo Leflunomid Teva povzroči nekatere krvne, jetrne,pljučne težave ali težave z živci v rokah in nogah.
Leflunomide Teva contains lactose.
Zdravilo Leflunomid Teva vsebuje laktozo.
Leflunomide Teva is a ‘generic medicine’.
Zdravilo Leflunomide Teva je generično zdravilo.
Leflunomide Teva is not recommended for use in patients below 18 years since efficacy and safety in juvenile rheumatoid arthritis (JRA) have not been established (see sections 5.1 and 5.2).
Zdravila Leflunomid Teva ni priporočljivo uporabljati za bolnike do 18. leta starosti, ker učinkovitost in varnost pri juvenilnem revmatoidnem artritisu (JRA) nista ugotovljeni (glejte poglavje 5.1 in 5.2).
Leflunomide Teva is not recommended for use in patients below 18 years since efficacy and safety in juvenile rheumatoid arthritis (JRA) have not been established (see sections 5.1 and 5.2).
Zdravila Leflunomid Teva ni priporočljivo uporabljati za bolnike do 18. leta starosti, ker učinkovitost in varnost pri juvenilnem revmatoidnem artritisu (JRA) nista ugotovljeni (glejte poglavji 5.1 in 5.2).
Leflunomide Teva is used to treat adult patients with active rheumatoid arthritis.
Zdravilo Leflunomid Teva se uporablja za zdravljenje odraslih bolnikov z aktivnim revmatoidnim artritisom ali aktivnim psoriatičnim artritisom.
Leflunomide Teva is used to treat adults with active rheumatoid arthritis (an immune system disease causing inflammation of the joints).
Zdravilo Leflunomide Teva se uporablja za zdravljenje odraslih z aktivnim revmatoidnim artritisom (boleznijo imunskega sistema, ki povzroča vnetje sklepov).
Leflunomide Teva tablets should be swallowed whole with plenty of water.
Tablete zdravila Leflunomid Teva pogoltnite celo in z veliko vode.
Leflunomide Teva tablets should be swallowed whole with sufficient amounts of liquid.
Tablete Leflunomid Teva je treba pogoltniti cele, z zadostno količino tekočine.
Leflunomide Teva treatment starts with a ‘loading dose’ of 100 mg once a day for three days, followed by a maintenance dose.
Zdravljenje z zdravilom Leflunomide Teva se začne z začetnim odmerkom 100 mg enkrat na dan prve tri dni, čemur sledi vzdrževalni odmerek.
Leflunomide was administered as a single oral 100 mg dose to 3 haemodialysis patients and 3 patients on continuous peritoneal dialysis (CAPD).
Leflunomid so aplicirali v enkratnem peroralnem 100-mg odmerku 3 hemodializnim bolnikom in bolnikom na kontinuirani ambulantni peritonealni dializi (CAPD).
Leflunomide Winthrop 10 mg
Leflunomid Winthrop 10 mg
Leflunomide Winthrop 10 mg film-coated tablets
Leflunomid Winthrop 10 mg filmsko obložene tablete
Leflunomide Winthrop 10 mg film-coated tablets are white to almost white and round.
Leflunomid Winthrop 10 mg filmsko obložene tablete so bele do skoraj bele barve in okrogle oblike.
Leflunomide Winthrop 10 mg film-coated tablets leflunomide
Leflunomid Winthrop 10 mg filmsko obložene tablete leflunomid
Leflunomide Winthrop 100 mg
Leflunomid Winthrop 100 mg
Leflunomide Winthrop 100 mg film-coated tablets
Leflunomid Winthrop 100 mg filmsko obložene tablete
Leflunomide Winthrop 100 mg film-coated tablets are white to almost white and round.
Leflunomid Winthrop 100 mg filmsko obložene tablete so bele do skoraj bele in okrogle oblike.
Leflunomide Winthrop 100 mg film-coated tablets leflunomide
Leflunomid Winthrop 100 mg filmsko obložene tablete leflunomid
Leflunomide Winthrop 20 mg
Leflunomid Winthrop 20 mg
Leflunomide Winthrop 20 mg film-coated tablets
Leflunomid Winthrop 20 mg filmsko obložene tablete
Leflunomide Winthrop 20 mg film-coated tablets are yellowish to ochre and triangular.
Leflunomid Winthrop 20 mg filmsko obložene tablete so rumenkaste do okraste barve in trikotne oblike.
Leflunomide Winthrop 20 mg film-coated tablets leflunomide
Leflunomid Winthrop 20 mg filmsko obložene tablete leflunomid
Leflunomide Winthrop belongs to a group of medicines called anti-rheumatic medicines.
Zdravilo Leflunomid Winthrop spada v skupino zdravil, ki jih imenujemo protirevmatična zdravila.
Leflunomide Winthrop can make you feel dizzy which may impair your ability to concentrate and react.
Zdravilo Leflunomid Winthrop lahko povzroči omotičnost, kar lahko prizadene sposobnost za koncentracijo in reagiranje.
Leflunomide Winthrop can occasionally cause some problems with your blood, liver, lungs or nerves in your arms or legs.
Občasno lahko zdravilo Leflunomid Winthrop povzroči nekatere krvne, jetrne, plučne težave, ali težave z živci v rokah in nogah.
Leflunomide Winthrop can occasionally cause some problems with your blood, liver, lungs, or nerves in your arms or legs.
Občasno lahko zdravilo Leflunomid Winthrop povzroči nekatere krvne, jetrne, pljučne težave ali težave z živci v rokah in nogah.
Leflunomide Winthrop can occasionally cause some problems with your blood, liver, lungs, or nerves in your arms or legs.
Občasno lahko zdravilo Leflunomid Winthrop povzroči nekatere krvne, jetrne,pljučne težave ali težave z živci v rokah in nogah .
Leflunomide Winthrop contains lactose
Zdravilo Leflunomid Winthrop vsebuje laktozo
Leflunomide Winthrop contains lactose.
Zdravilo Leflunomid Winthrop vsebuje laktozo.
Leflunomide Winthrop is a medicine that contains the active substance leflunomide.
Leflunomide Winthrop je zdravilo, ki vsebuje zdravilno učinkovino leflunomid.
Leflunomide Winthrop is contraindicated in patients with severe hypoproteinaemia or impairment of liver function (see section 4.3).
Zdravilo Leflunomid Winthrop je kontraindicirano pri bolnikih s hudo hipoproteinemijo ali okvarjenim delovanjem jeter (glejte poglavje 4.3).
Leflunomide Winthrop is contraindicated in pregnancy (see section 4.3).
Zdravilo Leflunomid Winthrop je kontraindicirano med nosečnostjo (glejte poglavje 4.3).
Leflunomide Winthrop is contraindicated in pregnancy(see section 4.3).
Zdravilo Leflunomid Winthrop je kontraindicirano med nosečnostjo (glejte poglavje 4.3).
Leflunomide Winthrop is not recommended for use in children and adolescents below 18 years of age.
Uporaba zdravila Leflunomid Winthrop ni priporočljiva pri otrocih in mladostnikih, ki so mlajši od 18 let.
Leflunomide Winthrop is not recommended for use in patients below 18 years since efficacy and safety in juvenile rheumatoid arthritis (JRA) have not been established (see sections 5.1 and 5.2).
Zdravila Leflunomid Winthrop ni priporočljivo uporabljati za bolnike do 18. leta starosti, ker učinkovitost in varnost pri juvenilnem revmatoidnem artritisu (JRA) nista ugotovljeni (glejte poglavje 5.1 in 5.2).
Leflunomide Winthrop is not recommended for use in patients below 18 years since efficacy and safety in juvenile rheumatoid arthritis (JRA) have not been established (see sections 5.1 and 5.2).
Zdravila Leflunomid Winthrop ni priporočljivo uporabljati za bolnike do 18. leta starosti, ker učinkovitost in varnost pri juvenilnem revmatoidnem artritisu (JRA) nista ugotovljeni (glejte poglavji 5.1 in 5.2).
Leflunomide Winthrop is used to treat adult patients with active rheumatoid arthritis or with active psoriatic arthritis.
Zdravilo Leflunomid Winthrop se uporablja za zdravljenje odraslih bolnikov z aktivnim revmatoidnim artritisom ali aktivnim psoriatičnim artritisom.
Leflunomide Winthrop is used to treat adults with active rheumatoid arthritis (an immune system disease causing inflammation of the joints) or active psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints).
Zdravilo Leflunomide Winthrop se uporablja za zdravljenje odraslih z aktivnim revmatoidnim artritisom (boleznijo imunskega sistema, ki povzroča vnetje sklepov) ali aktivnim psoriatičnim artritisom (boleznijo, ki povzroča rdeče, luskaste površine na koži in vnetje sklepov).
Leflunomide Winthrop may be taken with or without food.
Zdravilo Leflunomid Winthrop lahko jemljete s hrano ali brez nje.
Leflunomide Winthrop must not be used in patients with:
Zdravila Leflunomide Winthrop ne smejo uporabljati bolniki:
Leflunomide Winthrop must not be used in people who may be hypersensitive (allergic) to leflunomide, to teriflunomide (a breakdown product of leflunomide) or to any of the other ingredients.
Zdravila Leflunomide Winthrop ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) leflunomid, teriflunomid (produkt pri razgradnji leflunomida) ali katero koli drugo sestavino zdravila.
Leflunomide Winthrop must not be used in pregnant women, in women who can become pregnant and who are not using reliable contraception or during breast-feeding.
Zdravila Leflunomide Winthrop ne smejo uporabljati nosečnice, ženske, ki bi lahko zanosile in ne uporabljajo zanesljive kontracepcije, ali ženske, ki dojijo.
Leflunomide Winthrop tablets are for oral use.
Tablete Leflunomid Winthrop so za peroralno uporabo.
Leflunomide Winthrop treatment should be started and supervised by a specialist who has experience in the treatment of rheumatoid arthritis and psoriatic arthritis.
Zdravljenje z zdravilom Leflunomide Winthrop mora uvesti in nadzorovati zdravnik specialist, ki ima izkušnje z zdravljenjem revmatoidnega artritisa in psoriatičnega artritisa.
Leflunomide Winthrop was not as effective as methotrexate in the extension study.
V podaljšani študiji zdravilo Leflunomide Winthrop ni bilo tako učinkovito kot metotreksat.
Leflunomide Winthrop with food, drink and alcohol
Zdravilo Leflunomid Winthrop skupaj s hrano, pijačo in alkoholom
leflunomide, methotrexate and other medicines that affect the immune system (often called immunosuppressants or immunomodulators)
leflunomid, metotreksat ali druga zdravila, ki vplivajo na imunski sistem (pogosto jim pravimo imunosupresivna zdravila ali imunomodulatorji),
left
52 enot
left lower back or right lower back
levi spodnji del hrbta ali desni zgornji del hrbta
Left over Nplate in the vial must NEVER be re-used for another injection.
Preostanka zdravila Nplate v viali ne smete NIKOLI ponovno uporabiti za še eno injekcijo.
left upper arm or right upper arm
levi nadlaket ali desni nadlaket
left upper back or right upper back
levi zgornji del hrbta ali desni zgornji del hrbta
left upper back or right upper back left lower back or right lower back
levi zgornji del hrbta ali desni zgornji del hrbta levi spodnji del hrbta ali desni spodnji del hrbta
left upper chest or right upper chest (avoid breast)
levi zgornji del prsi ali desni zgornji del prsi (ne na dojko)
Left ventricular dysfunction
disfunkcija levega prekata
Left ventricular dysfunction was reported in 2.2% of patients in clinical studies with trastuzumab emtansine.
Disfunkcijo levega prekata so v kliničnih študijah s trastuzumabom emtanzinom zabeležili pri 2,2 % bolnikov.
Left ventricular dysfunction † (including congestive heart failure)**
disfunkcija levega prekata† (vključno s kongestivnim srčnim popuščanjem)
Left ventricular dysfunction, cardiac disorder, cardiac failure congestive, bundle branch block, tachycardia
disfunkcija levega prekata, srčna bolezen, kongestivno srčno popuščanje, levokračni blok, tahikardija
Left ventricular ejection fraction (LVEF) < 40% has been observed in patients treated with trastuzumab emtansine, and therefore symptomatic congestive heart failure (CHF) is a potential risk (see section 4.8).
Pri bolnikih, zdravljenih s trastuzumabom emtanzinom, so opažali iztisni delež levega prekata (LVEF) < 40 %, zato je možno simptomatsko kongestivno srčno popuščanje (glejte poglavje 4.8).
Left ventricular ejection fraction (LVEF) reduction/Left ventricular dysfunction
Znižanje iztisnega deleža levega prekata (LVEF)/disfunkcija levega prekata
Left Ventricular Mass Index (LVMi)
Indeks mase levega prekata (LVMi, Left Ventricular Mass index)
Leg cramps
Krči v nogah
Leg cramps, bone pain, musculoskeletal pain
krči v nogah, bolečine v kosteh, mišično- skeletne bolečine
Leg cramps.
krči v nogah
Leg or arm pain or swelling (which could be a symptom of blood clots in the deep veins of the leg or arm), chest pain or shortness of breath (which may be a symptom of blood clots in the lungs)
Bolečina ali oteklost noge ali roke (ki je lahko simptom krvnega strdka v globokih venah noge ali roke), bolečina v prsih ali kratka sapa (ki sta lahko simptoma krvnih strdkov v pljučih).
leg pain
bolečine v spodnjih udih
Leg pain (which could be a symptom of thrombosis), chest pain or shortness of breath (which may be a symptom of blood clots in the lungs, called pulmonary embolism)
bolečina v nogah (kar je lahko znak tromboze), bolečina v prsnem košu ali zasoplost (kar je lahko znak krvnih strdkov v pljučih, to stanje imenujemo pljučna embolija);
leg pain or stomach pain
bolečine v nogah ali trebuhu;
Leg ulcers
ulkusi na nogah
Leg ulcers are a common complication of Sickle Cell Syndrome, but have also been reported in patients treated with hydroxycarbamide.
Ulkusi na nogah so pogost zaplet pri srpasto celičnem sindromu, o njih pa so poročali tudi pri bolnikih, zdravljenih s hidroksikarbamidom.
Leganto 1 mg/24 h transdermal patch
Leganto 1 mg/24 h transdermalni obliž
Leganto 2 mg/24 h Leganto 4 mg/24 h Leganto 6 mg/24 h Leganto 8 mg/24 h Transdermal patch Rotigotine
Leganto 2 mg/24 h Leganto 4 mg/24 h Leganto 6 mg/24 h Leganto 8 mg/24 h Transdermalni obliž rotigotin
Leganto 2 mg/24 h transdermal patch rotigotine
Leganto 2 mg/24 h transdermalni obliž rotigotin
Leganto 3 mg/24 h transdermal patch
Leganto 3 mg/24 h transdermalni obliž
Leganto 4 mg/24 h instead of Leganto 2 mg/24 h) than your doctor told you to, contact your doctor or hospital for advice immediately, and follow their advice on changes of patches.
Leganto 4 mg/24 h, namesto Leganto 2 mg/24 h), kot vam je predpisal zdravnik, takoj obvestite svojega zdravnika ali bolnišnico in sledite njihovemu navodilu za odstranitev obližev.
Leganto 4 mg/24 h transdermal patch
Leganto 4 mg/24 h transdermalni obliž
Leganto 4 mg/24 h transdermal patch EU/1/11/695/028
Leganto 4 mg/24 h transdermalni obliž EU/1/11/695/028
Leganto 4 mg/24 h transdermal patch Leganto 6 mg/24 h transdermal patch Leganto 8 mg/24 h transdermal patch
Leganto 4 mg/24 h transdermalni obliž Leganto 6 mg/24 h transdermalni obliž Leganto 8 mg/24 h transdermalni obliž
Leganto 6 mg/24 h transdermal patch
Leganto 6 mg/24 h transdermalni obliž
Leganto 8 mg/24 h transdermal patch
Leganto 8 mg/24 h transdermalni obliž
Leganto 8 mg/24 h transdermal patch rotigotine
Leganto 8 mg/24 h transdermalni obliž rotigotin transdermalna uporaba
Leganto can cause skin reactions, such as reddening and itching.
Zdravilo Leganto lahko povzroči kožne reakcije, kot sta rdečica in srbenje.
Leganto contains sodium metabisulphite (E223)
Zdravilo Leganto vsebuje natrijev metabisulfit (E223)
Leganto contains the active substance rotigotine.
Zdravilo Leganto vsebuje zdravilno učinkovino rotigotin in je v obliki obliža, ki se ga uporabi na koži.
Leganto contains the active substance rotigotine.
Zdravilo Leganto vsebuje zdravilno učinkovino rotigotin.
Leganto is a transdermal patch.
Zdravilo Leganto je transdermalni obliž.
Leganto is applied once a day.
Zdravilo Leganto namestimo enkrat na dan.
Leganto is for transdermal use, a patch to be applied to the skin.
Zdravilo Leganto je za transdermalno uporabo, obliž uporabite na koži.
Leganto is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults.
Zdravilo Leganto je indicirano za simptomatično zdravljenje zmerne do hude oblike idiopatičnega sindroma nemirnih nog (RLS – Restless Legs Syndrome) pri odraslih.
Leganto is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults.
Zdravilo Leganto je indicirano za simptomatsko zdravljenje zmerne do hude idiopatične oblike sindroma nemirnih nog (RLS – Restless Legs Syndrome) pri odraslih.
Leganto is used on its own in early-stage disease, or in combination with levodopa (another medicine used in Parkinson’s disease) at any stage of the disease, including the later stages when levodopa starts becoming less effective; moderate to severe restless legs syndrome, a disorder where the patient has uncontrollable urges to move the limbs to stop uncomfortable, painful or odd sensations in the body, usually at night.
Zdravilo Leganto se uporablja kot samostojno zdravilo v zgodnji fazi bolezni ali v kombinaciji z levodopo (drugim zdravilom za zdravljenje Parkinsonove bolezni) v kateri koli fazi bolezni, vključno v poznih fazah, ko začne učinek levodope popuščati; zmernega do hudega sindroma nemirnih nog, tj. motnje, pri kateri ima bolnik nenadzorovano potrebo po premikanju okončin, da bi se znebil neprijetnih, bolečih ali nenavadnih občutkov v telesu, običajno ponoči.
Leganto is used to treat Restless Legs Syndrome (RLS) in adults that can be associated with discomfort in your legs or arms, urge to move around, sleep disturbance, tiredness or sleepiness during the day.
Zdravilo Leganto se uporablja za zdravljenje sindroma nemirnih nog (Restless Legs Syndrome - RLS) pri odraslih, , ki je lahko povezan z nelagodjem v vaših nogah ali rokah, s potrebo po premikanju, motnjami spanja, utrujenostjo ali zaspanostjo čez dan.
Leganto is used to treat Restless Legs Syndrome (RLS) in adults that can be associated with discomfort in your legs or arms, urge to move around, sleep disturbance, tiredness or sleepiness during the day.
Zdravilo Leganto se uporablja za zdravljenje sindroma nemirnih nog (Restless Legs Syndrome - RLS) pri odraslih, ki je lahko povezan z nelagodjem v vaših nogah ali rokah, s potrebo po premikanju, motnjami spanja, utrujenostjo ali zaspanostjo čez dan.
Leganto is used to treat the signs and symptoms of Parkinson’s disease in adults either alone or in combination with the medicine called levodopa.
Zdravilo Leganto se uporablja za zdravljenje znakov in simptomov Parkinsonove bolezni pri odraslih bodisi kot samostojno zdravljenje bodisi v kombinaciji z zdravilom imenovanim L-dopa.
Leganto is used to treat:
Zdravilo Leganto se uporablja za zdravljenje:
Leganto may cause abnormal thinking and behaviour.
Zdravilo Leganto lahko povzroči nenormalno mišljenje in vedenje.
Leganto may decrease blood pressure when you stand up; this effect may worsen by the medicine used to lower blood pressure. take sedating medicines (for example benzodiazepines, medicines used to treat mental conditions or depression) while you are using Leganto.
Zdravilo Leganto lahko zniža krvni tlak, ko stojite jemati sedative, na primer benzodiazepin (zdravila za zdravljenje duševnih motenj ali depresije)
Leganto may decrease blood pressure when you stand up; this effect may worsen by the medicine used to lower blood pressure. take sedating medicines (for example benzodiazepines, medicines used to treat mental conditions or depression) while you are using Leganto.
Zdravilo Leganto lahko zniža krvni tlak, ko stojite; ta učinek se lahko poslabša ob jemanju zdravila za zniževanje krvnega tlaka jemati sedative, na primer benzodiazepin (zdravila za zdravljenje duševnih motenj ali depresije)
Leganto may make you feel very drowsy, and you may fall asleep very suddenly.
Zaradi zdravila Leganto ste lahko zelo dremavi in lahko povsem nenadno zaspite.
Leganto should not be used by children because its safety and efficacy has not been established in children.
Zdravila Leganto ne smete uporabiti pri otrocih, ker njegova varnost in učinkovitost pri otrocih nista bili dokazani.
Leganto was more effective than placebo in treating Parkinson’s disease.
Zdravilo Leganto je bilo pri zdravljenju Parkinsonove bolezni učinkovitejše od placeba.
Leganto with food, drink and alcohol
Zdravilo Leganto skupaj s hrano, pijačo in akoholom
Leganto with food, drink and alcohol
Zdravilo Leganto skupaj s hrano, pijačo in alkoholom
Leganto with food, drink and alcohol
Zzdravilo Leganto skupaj s hrano, pijačo in alkoholom
Legemidlet er ikke lenger godkjent for salg
Zdravilo nima veā dovoljenja za promet
Leiomyoma (uterine fibroids) or endometriosis
leiomiomi (maternični miomi) ali endometrioza;
Leiomyosarcoma* Median (months)
Leiomiosarkom* Mediana (meseci)
Leishmania infantum Excreted Secreted Proteins (ESP) at least 100 µg
Leishmania infantum ekskrecijko-sekrecijski proteini (Excreted Secreted Proteins - ESP) najmanj 100 µg
Lek Pharmaceuticals d.d Verovskova 57
Verovskova 57
Lek Pharmaceuticals d.d.
Lek farmacevstka družba d.d.
Lek Pharmaceuticals d.d.
Lek farmacevtska družba d.d.
LEMTRADA 12 mg concentrate for solution for infusion
LEMTRADA 12 mg koncentrat za raztopino za infundiranje
LEMTRADA adjusts your immune system to limit its attacks on your nervous system.
Zdravilo LEMTRADA uravnava vaš imunski sistem in omejuje napade na živčni sistem.
LEMTRADA contains no antimicrobial preservatives and, therefore, care should be taken to ensure the sterility of the prepared solution.
Zdravilo LEMTRADA ne vsebuje protimikrobnih konzervansov, zato je potrebna previdnost, da se zagotovi sterilnost pripravljene raztopine.
LEMTRADA contains potassium and sodium
Zdravilo LEMTRADA vsebuje kalij in natrij
LEMTRADA contains the active substance alemtuzumab, which is used to treat a form of multiple sclerosis (MS) in adults, called relapsing remitting MS (RRMS).
Zdravilo LEMTRADA vsebuje zdravilno učinkovino alemtuzumab, ki se uporablja za zdravljenje oblike multiple skleroze (MS) pri odraslih bolnikih, ki ji pravimo recidivno-remitentna multipla skleroza (RRMS).
LEMTRADA has not been studied in patients with renal or hepatic impairment.
Zdravilo LEMTRADA ni bilo preučeno pri bolnikih z okvarjenim delovanjem ledvic ali jeter.
LEMTRADA infusion
LEMTRADA
LEMTRADA is indicated for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features (see sections 4.4 and 5.1).
Zdravilo LEMTRADA je indicirano za zdravljenje odraslih bolnikov z recidivno remitentno multiplo sklerozo (RRMS), ki imajo aktivno bolezen glede na klinične značilnosti ali značilnosti na slikanjih (glejte poglavji 4.4 in 5.1).
LEMTRADA may cause different types of thyroid disorders, including:
Zdravilo LEMTRADA lahko povzroči različne vrste bolezni ščitnice, vključno s:
LEMTRADA treatment should be initiated and supervised by a neurologist experienced in the treatment of patients with MS.
Zdravljenje z zdravilom LEMTRADA mora uvesti in nadzirati nevrolog z izkušnjami pri zdravljenju bolnikov z MS.
LEMTRADA will be given to you as an infusion into a vein.
Zdravilo LEMTRADA se daje kot infuzija v veno.
len/dex (N=353)
len/deks (n=353)
Lenalidomide
lenalidomid
Lenalidomide and Dexamethasone
lenalidomid in deksametazon
Lenalidomide binds directly to cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex that includes deoxyribonucleic acid (DNA) damage-binding protein 1(DDB1), cullin 4 (CUL4), and regulator of cullins 1 (Roc1).
Lenalidomid se veže neposredno na cereblon, ki je sestavni del encimskega kompleksa kulin-RING E3 ubikvitinske ligaze, ki vključuje beljakovino 1, ki se veže na poškodbe deoksiribonukleinske kisline (DNA) (DDB1- DNA damage-binding protein 1), kulin 4 (CUL4) in kulinski regulator 1 (Roc1- regulator of cullins 1).
Lenalidomide has an asymmetric carbon atom and can therefore exist as the optically active forms S(-) and R(+).
Lenalidomid ima asimetrični ogljikov atom, zato obstaja v dveh optično aktivnih oblikah, S(–) in R(+).